According to filings with the U.S. Securities and Exchange Commission, NGM Bio is raising up to $122,039,949.00 in new funding. Sources indicate that as part of senior management Chairman and Chief Executive Officer, David Goeddel played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About NGM Bio
NGM Bio is a biopharmaceutical company focused on discovering and developing novel, life-changing medicines for people whose health and lives have been disrupted by disease. The companys biology-centric drug discovery approach aims to seamlessly integrate interrogation of complex disease-associated biology and protein engineering expertise to unlock proprietary insights that are leveraged to generate promising product candidates and enable their rapid advancement into proof-of-concept studies. As explorers on the frontier of life-changing science, NGM Bio aspires to operate one of the most productive research and development engines in the biopharmaceutical industry. All therapeutic candidates in the NGM Bio pipeline have been generated by its in-house discovery engine, always led by biology and motivated by unmet patient need. In addition to a healthy balance sheet and cash runway, the company currently has four programs in active clinical development.

To learn more about NGM Bio, visit http://www.ngmbio.com/
NGM Bio Linkedin Page: https://www.linkedin.com/company/ngm-biopharmaceuticals/

Contact:
David Goeddel, Chairman and Chief Executive Officer
650-243-5555

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.